Your session is about to expire
← Back to Search
PTC596 + Radiotherapy for Brain Tumor
Study Summary
This trial is investigating the safety and efficacy of PTC596 in children and young adults with brain tumors. PTC596 is a novel drug that is being studied for its ability to improve the efficacy of radiation therapy. The trial is divided into two parts: the first part is designed to assess the maximum tolerated dose of PTC596 that can be given with radiation therapy, and the second part is a surgical study to assess the amount of the drug that is taken up by the tumor and surrounding tissue. The goals of the trial are to learn more about the safety and efficacy of PTC596 in this population, as well as to assess the quality of
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been recently diagnosed with a high-grade glioma that is not in my brainstem.I have a new diagnosis of DIPG and my doctor recommends a biopsy.My cancer is related to HIV or a solid organ transplant.I have been diagnosed with a specific brain tumor called DIPG without needing a tissue sample.I am between 1 and 21 years old.I have been diagnosed with oligodendroglioma or oligoastrocytoma.I am taking seizure medications listed in appendix II.I do not have any infections that are not responding to treatment.I am currently taking beta-blockers.I cannot take pills due to issues with my digestive system.I have a high-grade glioma and need more surgery to remove as much of it as possible before starting treatment.I don't have any significant ongoing illnesses or conditions.I am between 12 and 21 years old.My brain tumor is confirmed high-grade glioma or diffuse astrocytoma through biopsy.My brain tumor is a type known as high-grade glioma.I have moderate to severe lung problems.I can swallow whole capsules.I have not received any cancer treatment before.I can swallow pills.I have a new diagnosis of DIPG and can have a biopsy as recommended by my doctor.I have an active peptic ulcer or inflammatory bowel disease.I am currently taking duloxetine, alosetron, or theophylline.My brain tumor is high-grade and confirmed by biopsy.I am taking medication that can affect my heart's rhythm.I have been newly diagnosed with a brain tumor known as DIPG without needing a biopsy.I have serious wounds or fractures that are not healing.My heart, lungs, kidneys, liver, bones, and nervous system are all functioning well.I can take PTC596 through a tube in my nose or stomach.You have had an organ transplant in the past.You are currently taking other medications for cancer.I have been diagnosed with juvenile pilocytic astrocytoma.I am currently taking rifampin.I am on blood thinners like warfarin or heparin.I have a condition that affects how my body absorbs medicine or could cause stomach ulcers.I am mostly able to care for myself, regardless of my age.I do not have widespread DIPG or HGG cancer.I have been recently diagnosed with a high-grade glioma that is not in my brainstem.
- Group 1: Treatment (PTC596)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what extent has the population size for this medical test grown?
"Affirmative. The information on clinicaltrials.gov indicates that this medical experiment is actively searching for participants, which it posted and edited in August 2018 and September 2022 respectively. To complete the trial, 64 individuals are sought-after from 10 distinct sites."
Is there an opportunity to take part in this medical experiment?
"This medical trial is open to 64 individuals between the ages of one year and 21 years old who have been diagnosed with diffuse intrinsic pontine glioma. Additionally, those taking part must meet specific criteria: Age wise, they must be no younger than 12 months and no older than 21; Neurologically-speaking, patients ought to be able to ingest oral medications; Performance Level should stand at Karnofsky ≥ 50 for people over 16 years of age or Lansky ≥ 50 if under that age bracket (those unable to walk because of paralysis will still qualify as ambulatory); Diagnosis-wise it needs to either be a newly-diagn"
May individuals who are under the age of seventy partake in this research?
"The terms of participation for this medical trial stipulate that the minimum participant age must be 12 Months and the maximum is 21."
Are there available vacancies for potential participants in this experiment?
"Indeed, the clinicaltrials.gov website confirms that recruitment for this trial is still ongoing since its inception on August 1st 2018. It requires 64 patients to be sourced from 10 medical centres."
Has PTC596 acquired the endorsement of the Food and Drug Administration?
"The team at Power rated PTC596 a 1 on their safety scale, as this study is only in Phase 1. Thus far, there has been limited data collected to support the drug's efficacy and safety."
How many healthcare locations are currently undertaking this experiment?
"Currently, this experiment is being conducted in 10 clinical centres situated across the United States. These include Columbus, Chicago and Washington D.C., with other sites scattered around the nation. To reduce travel strain for participants, it can be beneficial to select a trial site located as close to you as possible."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger